Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors
- 13 July 2006
- journal article
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (11) , 1558-1560
- https://doi.org/10.1097/01.aids.0000237375.23692.f4
Abstract
Darunabir, formerly TMC114, is a new protease inhibitor (PI) under clinical development designed to be active against HIV strains resistant to currently available PI. The virological and immunological response to ritonavir-boosted darunabir was assessed in four heavily antiretroviral-experienced patients who had failed enfuvirtide and two or more previous ritonavir-boosted PI regimens, including tipranavir in one instance. All four patients reached undetectable plasma HIV-RNA levels within 8 weeks of therapy and experienced significant CD4 cell count gains.Keywords
This publication has 9 references indexed in Scilit:
- TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2005
- Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapyJournal of Clinical Virology, 2005
- Baseline Susceptibility of Primary Human Immunodeficiency Virus Type 1 to Entry InhibitorsJournal of Virology, 2003
- Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitorsInternational Journal of Antimicrobial Agents, 2002
- Rate of Virological Treatment Failure and Frequencies of Drug Resistance Genotypes among Human Immunodeficiency Virus-Positive Subjects on Antiretroviral Therapy in SpainJournal of Clinical Microbiology, 2002
- Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitorAIDS, 2002
- Human Immunodeficiency Virus Type 1 Genotypic and Pharmacokinetic Determinants of the Virological Response to Lopinavir-Ritonavir-Containing Therapy in Protease Inhibitor-Experienced PatientsAntimicrobial Agents and Chemotherapy, 2002
- World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testingAIDS, 2001
- A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1Antimicrobial Agents and Chemotherapy, 2000